Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to crush Hard-to-Treat leukemia

NCT ID NCT07224100

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of chemotherapy (DA-EPOCH) plus a targeted drug (ponatinib) in adults newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 33 people to see if this approach leads to a complete molecular response, meaning no detectable cancer cells. The goal is to improve initial treatment and reduce the chance of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

DA-EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) with or without rituximab plus ponatinib

What this could lead to

If successful, this could offer a more effective initial treatment for Ph+ ALL, potentially leading to better remission rates and longer survival.

What could go wrong

This is an early phase II trial with only 33 participants, so results may not apply to everyone. Chemotherapy and ponatinib can cause serious side effects like infections, heart problems, and blood clots.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact